Aktuelle Wissenschafts-News

Moroni G, Depetri F, Del Vecchio L et al. Low-dose rituximab is poorly effective in patients with primary membranous nephropathy. Nephrol Dial Transplant 2017; 32(10): 1691-96 mehr...

Torres VE, Chapman AB, Devuyst O et al. Tolvaptan in Later-Stage Autosomal Dominant Polycystic Kidney Disease. N Engl J Med 2017 Nov; 377(20): 1930-42 mehr...

Knoop T, Vikse BE, Mwakimonga A et al. Long-term outcome in 145 patients with assumed benign immunoglobulin A nephropathy. Nephrol Dial Transplant 2017 Nov; 32(11): 1841-50 mehr...

Rosenzwajg M, Languille E, Debiec H et al. B- and T-cell subpopulations in patients with severe idiopathic membranous nephropathy may predict an early response to rituximab. Kidney Int 2017; 92(1): 227-37 mehr...

Bowe B, Xie Y, Li T et al. Particulate Matter Air Pollution and the Risk of Incident CKD and Progression to ESRD. J Am Soc Nephrol 2018; 29(1): 218-30 mehr...

Suwabe T, Ubara Y, Sekine A et al. Effect of renal transcatheter arterial embolization on quality of life in patients with autosomal dominant polycystic kidney disease. NDT 2017; 32(7): 1176-83 mehr...

Chaudry MS, Carlson N, Gislason GH et al. Risk of Infective Endocarditis in Patients with End Stage Kidney Disease. Clin JASN 2017 Nov; 12(11): 14-1822 mehr...

Sumida K, Molnar MZ, Potukuchi PK et al. Association between vascular access creation and deceleration of estimated glomerular filtration rate decline in late-stage chronic kidney disease patients transitioning to end-stage renal disease. NDT 2017; 32(8): 1330-7 mehr...

Berlowitz DR, Foy CG, Kazis LE et al. SPRINT Research Group. Effect of Intensive Blood-Pressure Treatment on Patient-Reported Outcomes. NEJM 2017; 377(8): 733-44 mehr...